U.S. Markets closed

Pacira BioSciences, Inc. (PCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
57.59+0.44 (+0.77%)
At close: 4:00PM EDT
57.59 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close57.15
Open57.45
Bid57.65 x 1100
Ask66.25 x 1000
Day's Range56.78 - 58.10
52 Week Range48.23 - 80.00
Volume266,342
Avg. Volume350,787
Market Cap2.535B
Beta (5Y Monthly)1.06
PE Ratio (TTM)17.32
EPS (TTM)3.33
Earnings DateOct 27, 2021 - Nov 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est79.14
  • GlobeNewswire

    Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries

    Study demonstrating safety and tolerability of EXPAREL published in Journal of Clinical AnesthesiaPARSIPPANY, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that full results of its Phase 3 PLAY study of EXPAREL® (bupivacaine liposome injectable suspension) administered via infiltration in pediatric patients undergoing spinal or cardiac surgeries have been published in Journal of Clinical Anesthesia. The study, which was designed to establish the

  • GlobeNewswire

    Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021

    -- Expanding EXPAREL utilization continues to drive growth with average daily sales at 109% of August 2020 -- -- More than nine million patients treated with EXPAREL as of August 2021 -- PARSIPPANY, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales. EXPAREL® (bupivacaine liposome injectable suspension) net pr

  • GlobeNewswire

    Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    PARSIPPANY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 AM ET on Monday, September 13, 2021. Pre-recorded audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira BioSciences, Inc. (Nasda